Low-density lipoprotein size and cardiovascular risk assessment
Open Access
- 1 January 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 99 (1), 1-14
- https://doi.org/10.1093/qjmed/hci154
Abstract
A predominance of small, dense low-density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease and evidences suggests that both quality (particularly small, dense LDL) and quantity may increase cardiovascular risk. However, other authors have suggested that LDL size measurement does not add information beyond that obtained by measuring LDL concentration, triglyceride levels and HDL concentrations. Therefore, it remains debatable whether to measure LDL particle size in cardiovascular risk assessment and, if so, in which categories of patient. Therapeutic modulation of LDL particle size or number appears beneficial in reducing the risk of cardiovascular events, but no clear causal relationship has been shown, because of confounding factors, including lipid and non-lipid variables. Studies are needed to investigate the clinical significance of LDL size measurements in patients with coronary and non-coronary forms of atherosclerosis; in particular, to test whether LDL size is associated with even higher vascular risk, and whether LDL size modification may contribute to secondary prevention in such patients.Keywords
This publication has 98 references indexed in Scilit:
- Should we measure routinely the LDL peak particle size?International Journal of Cardiology, 2006
- Gemfibrozil Reduces Small Low-Density Lipoprotein More in Normolipemic Subjects Classified as Low-Density Lipoprotein Pattern B Compared With Pattern AThe American Journal of Cardiology, 2005
- Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia—a nuclear magnetic resonance studyInternational Journal of Cardiology, 2005
- Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysmAtherosclerosis, 2004
- Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetesDiabetes/Metabolism Research and Reviews, 2002
- Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemiaAmerican Heart Journal, 2002
- Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemiaExperimental and Clinical Endocrinology & Diabetes, 2002
- Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrateDiabetes/Metabolism Research and Reviews, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemiaThe American Journal of Cardiology, 1995